国泰海通｜医药：MFN谈判接近尾声，14家药企达成协议

Core Viewpoint - The U.S. government has reached a Most Favored Nation (MFN) pricing agreement with 14 pharmaceutical companies, which includes provisions for price reductions and tax exemptions, but the overall impact is expected to be limited [1][2]. Group 1: Agreement Details - Nine major pharmaceutical companies, including Amgen, Bristol-Myers Squibb, and Gilead, have agreed to lower prices for certain chronic disease medications, including those for type 2 diabetes and rheumatoid arthritis [1]. - The agreement mandates that all listed innovative drugs from these companies must adhere to MFN pricing [1]. - A total investment of at least $150 billion will be made by these companies for domestic production in the U.S. [1]. Group 2: Revenue Impact - The price reductions are primarily focused on Medicaid and direct-to-patient sales channels, which represent a limited portion of the companies' overall revenue [2]. - Medicaid beneficiaries are typically low-income individuals, making it challenging for them to purchase medications directly through the DTP model [2]. Group 3: Tax Exemptions - All 14 pharmaceutical companies involved in the agreement will receive a three-year exemption from tariffs, alleviating previous uncertainties regarding tariffs and trade policies in the pharmaceutical sector [2].